Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 EP520 | DOI: 10.1530/endoabs.70.EP520

Complejo Hospitalario de Navarra, Spain


Introduction: Hypothyroidism during pregnancy has been asociated with adverse maternal and neonatal outcomes. During pregnancy, maternal levothyroxine (LT4) dose requirements increase. The aim of this study is to determine the increase of LT4 doses during pregnancy in pregestational hypothyroid women.

Methods: We included 76 hypothyroid pregnant women. We analyzed analytical and clinical characteristics of these patients, as well as the increase of LT4 requirement during pregnancy. We used the statistical software SPSS version 20.

Results: Fifty-two women had autoimmune hypothyroidism (68.4%). The mean prepregnancy TSH was 2.46 ± 1.25 mU/l and the prepregnancy LT4 requeriment was 75.3 ± 32.3 µg/d. An increase in the LT4 dose was necessary in 64 women (84.2%). The mean LT4 requirement increased 44 ± 45 percent. Women with LT4 ≤ 50 µg/d increased LT4 by 63%, those between 51–100 µg/d and > 100 µg/d increased by 33% and 25% respectively (P = 0.008). Women with higher levels of anti-Tg antibodies required a higher LT4 dose (70% vs. 37%, P = 0.025). There is also a higher dose increase in women with prepregnancy TSH > 2.5 mU/l, but these differences were not statistically significant.

Conclusion: Most pregestational hypothyroid women require an increase in daily substitutive doses of LT4 during pregnancy. The mean LT4 requirement increased 45% percent during pregnancy. Women with lower prepregnancy LT4 requirement and women with higher levels of anti-Tg antibodies needed a higher dose increase.

Volume 70

22nd European Congress of Endocrinology

Online
05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.